SCHEMBL3979162

SCHEMBL3979162

CC(=O)Nc1ccc(CC(=O)Nc2c(N)n(Cc3ccoc3)c(=O)n(Cc3ccccc3)c2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.48
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NLRP3 Q96P20 1/20 0.40
MAPT P10636 3/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ERCC5 P28715 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
GAA P10253 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
ADORA2B P29275 1/20 0.37
NAT1 P18440 1/20 0.37
PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3981788 0.84 PKM (0.47) PKMNPC1RAB9AHTTSMN1; SMN2
SCHEMBL3983281 0.77 NLRP3 (0.46) PKMNPC1RAB9AHTTSMN1; SMN2
SCHEMBL3979238 0.73 PCK1 (0.60) PKMSMN1; SMN2RXFP1ADORA2B
SCHEMBL3980723 0.71 PCK1 (0.42) PKMHTTSMN1; SMN2NLRP3MEN1
SCHEMBL3978774 0.69 MAPT (0.41) NPC1RAB9AHTTSMN1; SMN2NLRP3
SCHEMBL7383648 0.68 ADORA2B (0.48) PKMRAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL3979338 0.67 PCK1 (0.47) HTTNLRP3MAPTMEN1KMT2A
SCHEMBL3981926 0.67 PCK1 (0.51) RXFP1ADORA2B
SCHEMBL4812436 0.66 PKM (0.60) PKMNPC1RAB9AHTTSMN1; SMN2
SCHEMBL25669896 0.66 EPHX2 (0.67) NPC1RAB9ASMN1; SMN2NLRP3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515972-B1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY HOFFMANN LA ROCHE (CH) 2009-05-13 EP disclosed
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1515972-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed
WO-2003106459-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL PKM 209/4885NPC1 820/4885RAB9A 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.